PMV Pharmaceuticals Inc. (NASDAQ:PMVP) finished Wednesday with an addition of $1.88 to close at $8.67, an upside of 27.69 percent. An average of 533,420 shares of common stock have been traded in the last five days. There was a gain of $2.07 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 431,905 shares traded, while the 50-day average volume stands at 388,790.
PMVP stock has increased by 14.99% in the last month. The company shares reached their 1-month lowest point of $6.00 on 07/17/23. With the stock rallying to its 52-week high on 01/04/23, shares of the company touched a low of $3.84 and a high of $17.77 in 52 weeks. It has reached a new high 2 times so far this year and lost -0.34% or -$0.03 in price. In spite of this, the price is down -51.22% from the 52-week high.
Valuation Metrics
PMV Pharmaceuticals Inc. (PMVP) stock’s beta is 0.95. Other valuation ratios to consider include the price-to-book (PB) ratio at 1.72.
Financial Health
The quick ratio of PMV Pharmaceuticals Inc. for the three months ended March 30 was 22.00, and the current ratio was 22.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30. Its gross profit as reported stood at $3.71 million compared to revenue of $77.04 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, PMV Pharmaceuticals Inc.’s return on assets was -26.70%.
Earnings Surprise
For the three-month period that ended March 30, PMV Pharmaceuticals Inc. had $86.49 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$19.13 million in the quarter, while revenues of -$19.35 million were grew 3.66%. The analyst consensus anticipated PMV Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.46 per share, but it turned out to be -$0.42, a 8.70% surprise. For the quarter, EBITDA amounted to -$22.02 million. Shareholders own equity worth $45.77 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at PMV Pharmaceuticals Inc. (PMVP) price momentum. RSI 9-day as of the close on 09 August was 82.31%, suggesting the stock is Overbought, with historical volatility in this time frame at 121.65%.
As of today, PMVP’s price is $7.02 +31.36% or $2.07 from its 5-day moving average. PMVP is currently trading +16.38% higher than its 20-day SMA and +52.11% higher than its 100-day SMA. However, the stock’s current price level is +60.85% above the SMA50 and -25.19% below the SMA200.
The stochastic %K and %D were 63.65% and 51.78%, respectively, and the average true range (ATR) was 0.60. With the 14-day stochastic at 99.17% and the average true range at 0.55, the RSI (14) stands at 75.50%. The stock has reached 0.49 on the 9-day MACD Oscillator while the 14-day reading was at 0.62.
Analyst Ratings
Oppenheimer upgraded PMV Pharmaceuticals Inc. (NASDAQ: PMVP) to a an Outperform rating in its most recent analyst report. Previously, the stock was rated as a Perform. The consensus rating for PMV Pharmaceuticals Inc. (PMVP) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PMVP, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is PMVP’s price target for the next 12 months?
Analysts predict a range of price targets between $15.00 and $35.00, with a median target of $19.00. Taking a look at these predictions, the average price target given by analysts for PMV Pharmaceuticals Inc. (PMVP) stock is $21.50.
